Breakthrough biosimilar ANYRA™ expands access to advanced biologic therapy for sight-threatening retinal diseases Agreement with Regeneron and Bayer strengthens innovation ...
Approval covers 100 mg and 150 mg strengths; drug used in treating ovarian, breast, pancreatic and prostate cancers With this, ...
The firm reports double-digit growth in Q2, revenue up 20% Research & Development (R&D) investments for the quarter stands at ...
Usnoflast, is a “First-in-class” NLRP3 inhibitor to demonstrate proof-of-concept in Phase 2(a) clinical study in ALS patients Usnoflast was well-tolerated ...
Zydus receives final approval from USFDA for Amantadine extended-release capsules 68.5 mg and tentative approval for 137 mg Eligible for ...
Company receives USFDA approval for Valbenazine Capsules Revenue from operations at Rs. 62,075 mn, up 21% YoY Research & Development ...
